Cargando…

Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients

BACKGROUND: This meta-analysis aimed to test the hypothesis that the HER2-positive metastatic breast cancer (mBC) patients treated with anti-HER2 antibodies in trial intervention arms have a greater prolongation of overall survival (OS) than of progression-free survival (PFS) and this extra-prolonga...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, I-Chun, Hu, Fu-Chang, Lin, Ching-Hung, Huang, Shu-Min, Chang, Dwan-Ying, Cheng, Ann-Lii, Lu, Yen-Shen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321956/ https://www.ncbi.nlm.nih.gov/pubmed/34298300 http://dx.doi.org/10.1016/j.breast.2021.07.006

Ejemplares similares

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?
por: Forsythe, Anna, et al.
Publicado: (2018)

The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
por: Mendes, Diogo, et al.
Publicado: (2015)

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
por: Bartsch, R, et al.
Publicado: (2012)

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer
por: Forsythe, Anna, et al.
Publicado: (2018)

HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis
por: Erickson, Anders W, et al.
Publicado: (2020)

Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?
por: Kümmel, Sherko, et al.
Publicado: (2018)

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2023)

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
por: Yang, Liu, et al.
Publicado: (2022)

HER3 over-expression and overall survival in gastrointestinal cancers
por: Wang, Yadong, et al.
Publicado: (2015)

Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors
por: Weide, Rudolf, et al.
Publicado: (2014)

Preliminary association of circulating tumor cells (CTCs) pre- and post-AdHER2 dendritic cell vaccination with overall survival in patients with metastatic HER2+ solid tumors
por: Tomita, Yusuke, et al.
Publicado: (2015)

Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer
por: Cordero, Alex, et al.
Publicado: (2021)

Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
por: Jacobson, Anne
Publicado: (2022)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

TXNIP interaction with the Her-1/2 pathway contributes to overall survival in breast cancer
por: Nie, Weiwei, et al.
Publicado: (2014)

Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer
por: dos Santos, Giovana Tavares, et al.
Publicado: (2017)

Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature
por: Ge, Jennifer Y., et al.
Publicado: (2021)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer
por: Gallagher, Christopher M., et al.
Publicado: (2016)

HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis
por: Tan, Ryan Shea Ying Cong, et al.
Publicado: (2022)

Metastatic colorectal cancer-prolonging overall survival with targeted therapies
por: Dattatreya, Satya
Publicado: (2013)

HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers
por: Wang, Tonghui, et al.
Publicado: (2017)

HER2–CDH1 Interaction via Wnt/B-Catenin Is Associated with Patients’ Survival in HER2-Positive Metastatic Gastric Adenocarcinoma
por: De Re, Valli, et al.
Publicado: (2022)

Metastatic Breast Cancer Survival according to HER2 and Topo2a Gene Status
por: Todorović-Raković, N., et al.
Publicado: (2009)

Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
por: Maron, Steven B., et al.
Publicado: (2023)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review
por: Reinert, Tomás, et al.
Publicado: (2017)

The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling
por: Hsu, Wan-Tseng, et al.
Publicado: (2018)

Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival
por: Yardley, Denise A, et al.
Publicado: (2015)

Multistate model for pharmacometric analyses of overall survival in HER2‐negative breast cancer patients treated with docetaxel
por: Krishnan, Sreenath M., et al.
Publicado: (2021)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer
por: Gogate, Anagha, et al.
Publicado: (2023)

Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine
por: Nieto, Celia, et al.
Publicado: (2020)

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2021)

Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry
por: Meegdes, Marissa, et al.
Publicado: (2023)

HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
por: Liu, Zimin, et al.
Publicado: (2021)

Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lux, Michael Patrick, et al.
Publicado: (2019)

A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival
por: Barrón-Gallardo, Carlos A., et al.
Publicado: (2022)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_o6connm2ian2rk4uil0333uokj